This open-label multicenter study evaluated the human monoclonal antibody, cemiplimab, for treatment of advanced cutaneous squamous-cell carcinoma. Cemiplimab is a high-affinity monoclonal antibody directed against programmed death 1 (PD-1). Source: AAO
This week, a drop-sized lawsuit is squeezed out of deliberations by the U.S. Supreme Court, an orange a day may keep macular degeneration away and Japan’s Takeda is one step closer to buying Shire for $62 billion. Source: AAO
This retrospective study evaluated the sensitivity and specificity of brain MRI to predict endocrinopathy in children with optic nerve hypoplasia (ONH). Source: AAO
Alleye, a mobile medical application developed to monitor progression of patients with AMD, was approved by the FDA earlier this week. Source: AAO
Due to lack of sterility assurance, the FDA is urging healthcare professionals not to use sterile drug products produced and distributed by Ranier’s Compounding Laboratory, Ranier’s Pharmacy and Ranier’s RX Laboratory, Jeannette, Pennsylvania. Source: AAO
Investigators report data from 2 randomized phase 3 trials assessing the safety and efficacy of lampalizumab, a complement factor D inhibitor, for the treatment of geographic atrophy. Source: AAO
This study describes the 3-year changes in anterior and posterior corneal irregular astigmatism and curvature after small incision lenticule extraction. Source: AAO
This cross-sectional study explores whether ocular features of keratoconjunctivitis sicca (KCS) or symptoms of dry eye disease are associated with depression in women with Sjögren syndrome (SS). Source: AAO
This week, researchers dismantle glaucoma disparities, diets rich in fatty fish may stave off AMD and new nasal sprays infuse the pharma pipeline with promise. Source: AAO
In this study, researchers retrospectively assessed functional outcomes when patients underwent corneal refractive procedures while taking the acne drug isotretinoin (Acutane). Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
